News
After a no in sickle cell, NICE OKs Casgevy for thalassaemia
Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it dow
